Scarica l'app Stockscreener
3.959
4.68%
0.169
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.79
Aprire:
$3.8
Volume 24 ore:
708.17K
Relative Volume:
0.89
Capitalizzazione di mercato:
$168.90M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-0.9059
EPS:
-4.37
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
-3.93%
1M Prestazione:
+11.13%
6M Prestazione:
-67.10%
1 anno Prestazione:
-36.82%
Intervallo 1D:
$3.72
$4.15
Intervallo di 1 settimana:
$3.71
$4.285
Portata 52W:
$2.10
$14.22
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VSTM | 3.959 | 168.90M | 3.64M | -87.37M | -86.46M | -4.37 |
| VRTX | 449.99 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.15 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.33 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
KRAS Inhibitors Market Report 2034: Epidemiology Data, - openPR
Data-Based Insights About Verastem Inc (VSTM) - Stocks Register
OrbiMed Advisors LLC's Strategic Acquisition of Verastem Inc Sha - GuruFocus.com
Alyeska Investment Group L.P.'s Strategic Acquisition of Veraste - GuruFocus.com
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives $14.57 Average PT from Analysts - MarketBeat
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision - Investing.com India
Verastem's SWOT analysis: oncology firm's stock faces pivotal FDA decision By Investing.com - Investing.com Canada
Stonepine Capital Management, LLC Increases Stake in Verastem Inc - GuruFocus.com
Such Is The Power Of Verastem Inc (NASDAQ: VSTM) - Stocks Register
Verastem (NASDAQ:VSTM) Stock Rating Lowered by StockNews.com - Defense World
Verastem CEO Paterson sells $3,118 in common stock - Investing.com
Verastem CEO Paterson sells $3,118 in common stock By Investing.com - Investing.com UK
Verastem Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem: Q3 Earnings Snapshot - The Washington Post
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Chugai PharmaceuticalVerastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Avutometinib With Defactinib for Recurrent KRAS Mutant LGSOC Completes Rolling New Drug Application - Pharmacy Times
Verastem Oncology submits NDA for ovarian cancer treatment - Yahoo Finance
Verastem (FRA:2VSA) Owner Earnings per Share (TTM) : -3.30 (As of Jun. 2024) - GuruFocus.com
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - StockTitan
Verastem Oncology to Participate in Upcoming Investor Conferences - BioSpace
SG Americas Securities LLC Purchases New Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem's SWOT analysis: ovarian cancer drug maker's stock faces pivotal year - Investing.com India
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Verastem preps an NDA as the stock struggles - BioWorld Online
Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Verastem Holders Endure Difficult Day, Analysts Holding Firm (VSTM) - AskTraders
Truist keeps $15 target on Verastem amid sell-off By Investing.com - Investing.com UK
Verastem Advances Cancer Treatment with Promising Trial Results - TipRanks
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting - StockTitan
This trade activity should not be overlooked: Verastem Inc (VSTM) - SETE News
Verastem Inc (VSTM) stock: A year of ups and downs - US Post News
Verastem CFO sells shares worth $17 to cover tax obligations By Investing.com - Investing.com Canada
Verastem CFO sells shares worth $17 to cover tax obligations - Investing.com India
Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting - StockTitan
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Verastem whipsaws after updates for cancer drug combo - MSN
Taking the lead: Verastem Inc (VSTM) - SETE News
Guggenheim’s latest rating for VSTM stock - Knox Daily
Verastem Inc’s results are impressive - US Post News
Nantahala Capital Management LLC Purchases Shares of 400,000 Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Inc (VSTM) Stock: A Year of Decreases and Increases - The InvestChronicle
Guggenheim Initiates Coverage of Verastem (VSTM) with Buy Recommendation - Nasdaq
Nantahala Capital Management LLC Takes Position in Verastem, Inc. (NASDAQ:VSTM) - MarketBeat
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):